Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$0.33 -0.05 (-15.15%)
2/9/2010 3:55 PM

NeoPharm, Inc. (NEOL.PK)

CAPS Rating:
No stars

A biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of various cancers.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

NEOL.PK doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

26 Outperforms
0 Underperforms
 

All-Stars

3 Outperforms
0 Underperforms
 

Members bullish on NEOL.PK are also bullish on:

  • None

Members bearish on NEOL.PK are also bearish on:

  • None

Ticker Tags

Defensive (1457), Biotechnology (220), Micro Cap (4701), Healthcare (711)
Suggest a tag

NeoPharm, Inc. At A Glance

Current Price: $0.33
Last Trade Time: 2/9/2010 3:55 PM
Open: $0.28
Previous Close: $0.33
Daily Range: $0.28 - $0.33
52-Week Range: $0.04 - $0.55
Volume: 8,086
Market Cap: $8.55M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

NEOL.PK VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

0

NeoPharm, Inc. (NEOL.PK)

Avatar bjgeissler (< 20) Submitted: 10/17/06 11:46 PM

Large insider buying and BIG MO on the side of the stock recently. Not to mention Biotech is once again getting the attention it deserves. Excited about 2007 and beyond for this company.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 4 of 4  

Recs

0

 (NEOL.PK)

Avatar forehandlob (< 20) Submitted: 10/27/06 9:13 PM : Outperform Start Price: $6.97 NEOL.PK Score: -77.97

expect anti-cancer products to score

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NEOL.PK)

Avatar gfang (< 20) Submitted: 10/23/06 2:37 AM : Outperform Start Price: $7.87 NEOL.PK Score: -79.14

heavy insider buying; promising stage III trial

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NEOL.PK)

Avatar bjgeissler (< 20) Submitted: 10/17/06 11:46 PM : Outperform Start Price: $7.90 NEOL.PK Score: -78.82

Large insider buying and BIG MO on the side of the stock recently. Not to mention Biotech is once again getting the attention it deserves. Excited about 2007 and beyond for this company.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NEOL.PK)

Avatar lim38784 (84.22) Submitted: 10/13/06 12:38 PM : Outperform Start Price: $7.44 NEOL.PK Score: -79.07

Its lead drug therapy is currently in Phase III clinical trials.
In a series of blind trials, patients treated lived for an average of 55.6 weeks versus 28 weeks with currently available treatments. While this may not seem like a massive breakthrough (i.e., a cure), it is twice as effective as the current treatment.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 4 of 4  

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 296ms